Boston Scientific and CareFusion Trading Actively Higher Before Earnings

Boston Scientific Corp. (NYSE:BSX) will unveil its latest earnings on Thursday, February 2, 2012. The average estimate of analysts is for profit of 8 cents per share, a decline of 60% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 9 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 8 cents during the last month. For the year, analysts are projecting net income of 44 cents per share, a decline of 8.3% from last year.

Last quarter, the company beat estimates by 7 cents, coming in at profit of 15 cents a share versus the estimate of net income of 8 cents a share. It marked the fourth straight quarter of beating estimates. On average, analysts predict $1.91 billion in revenue this quarter, a decline of 4.5% from the year ago quarter. Analysts are forecasting total revenue of $7.68 billion for the year, a decline of 1.7% from last year’s revenue of $7.81 billion.

Competitors to Watch: Medtronic, Inc. (NYSE:MDT), St. Jude Medical, Inc. (NYSE:STJ), Merit Medical Systems, Inc. (NASDAQ:MMSI), C.R. Bard, Inc. (NYSE:BCR), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Stryker Corporation (NYSE:SYK), Teleflex Incorporated (NYSE:TFX), AngioDynamics, Inc. (NASDAQ:ANGO), and The Spectranetics Corp. (NASDAQ:SPNC).

CareFusion
(NYSE:CFN) will unveil its latest earnings on Thursday, February 2, 2012. The average estimate of analysts is for profit of 43 cents per share, a decline of 2.3% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 47 cents. Between one and three months ago, the average estimate was unchanged. It has since dropped over the last month. Analysts are projecting profit to rise by 9.7% versus last year to $1.81.

The company met estimates last quarter after beating the forecasts in the prior two. In the first quarter, the company reported net income of 33 cents per share versus a mean estimate of profit of 33 cents per share. In the fourth quarter of the last fiscal year, the company beat estimates by one cent. Analysts are projecting a decline of 8.6% in revenue from the year-earlier quarter to $914.2 million.

Competitors to Watch: Teleflex Incorporated (NYSE:TFX), Covidien plc (NYSE:COV), Thermo Fisher Scientific Inc. (NYSE:TMO), Cardinal Health, Inc. (NYSE:CAH), Masimo Corporation (NASDAQ:MASI), Angeion Corporation (NASDAQ:ANGN), NeuroMetrix, Inc. (NASDAQ:NURO), Baxter International Inc. (NYSE:BAX), C.R. Bard, Inc. (NYSE:BCR), and Stryker Corporation (NYSE:SYK).

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com